Pharmafile Logo

Strategic Advisory Group of Experts

- PMLiVE

NHS England to offer millions of children flu vaccines from September

The rollout is part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

World Health Organization classifies EG.5 as a COVID-19 ‘variant of interest’

The strain accounted for over 17% of COVID-19 cases between 17 and 23 July

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

- PMLiVE

US NIH launches mid-stage long COVID trials to evaluate at least four treatments

One trial will test a longer dosing regimen of Pfizer’s antiviral COVID-19 drug Paxlovid

Can Cinderella save us?

New study finds vaccines could avert 500,000 antimicrobial resistance deaths each year

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

International Respiratory Coalition urges policymakers to help lift disease burden

The societal and economic cost of respiratory disease in Europe is reportedly over €600bn

- PMLiVE

World Health Organization publishes research agenda for antimicrobial resistance

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

FDA advisory committee backs updated COVID-19 vaccines targeting XBB variants

The XBB.1.5 variant accounted for nearly 40% of all US COVID-19 cases as of early June

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links